Project description
Type 2 diabetes prediction using epigenetic biomarkers
Type 2 Diabetes Mellitus (T2DM) is a prevalent disease with significant global impact. Prevailing predictive models are limited to pre-diabetic stages and hinder proactive intervention. Funded by the European Research Council, the PredRegNetworks project introduces a groundbreaking approach using novel epigenetic biomarkers. The idea is based on the role of enhancers and silencers in regulatory networks. By leveraging this knowledge, the proposed disease-prediction models are expected to achieve clinical-level accuracy even in non-diabetic individuals. These innovative models can identify at-risk individuals well before clinical symptoms manifest, offering a transformative opportunity for early intervention and preventive treatments. Validation of this approach could lead to the development of a pioneering clinical test for combatting T2D.
Objective
Type 2 Diabetes Mellitus (T2DM) is a heterogeneous disease, associated with mortality and severe morbidity, and affecting hundreds of millions of people around the globe. Despite some misconception accepted in the public, current models to predict the onset of T2DM have insufficient power, and are generally limited to individuals that already progressed into pre-diabetes states, at which the assignment of disease-preventing treatments is largely ineffective. Clinical-level prediction power (AUC>0.9) among non-diabetic individuals would enable effective pre-emptive strategies, but the way to produce such predictions remined unknown. Based on a new understanding of enhancer-silencer regulatory networks, I have developed a new class of supreme epigenetic biomarkers. Disease-prediction models that built on the basis of these novel understanding and biomarkers, significantly overpower the best currently-available prediction models. Importantly, these pioneering models can identify the people at risk well before the appearance of any clinical symptoms. Strong preliminary evidence signified the potential to develop the first clinical test to identify the risk to develop T2DM and associated diseases among non-pre-diabetic individuals at the required prediction power, and in time to deliver effective disease-preventing treatments. Validation of these results and demonstration of the effectiveness of the new clinical-level test will allows the directions of the effective (though expensive) preventing treatments to the people at risk, thus dramatically improve the way we are dealing with this harmful disease.
Fields of science
Keywords
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Funding Scheme
HORIZON-ERC-POC - HORIZON ERC Proof of Concept GrantsHost institution
91904 Jerusalem
Israel